Who
Tanya Lewis
Director
Company insider
Files Form 4 as: Director, DiaMedica Therapeutics; Chief Dev. Op. Officer, Replimune Group; EVP, Chief Reg. Affairs, Karyopharm Therapeutics; VP Regulatory and Quality, Vion Pharmaceuticals.
In numbers
- Trades disclosed
- 29
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $645K
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 10 Dec 2008
- Last trade
- 1 Jun 2026
- Last filed
- 3 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Jun 2026filed 3 Jun 2026 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,412 at $0.00 | filing |
| 1 Jun 2026filed 3 Jun 2026 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,412 at $0.00 | filing |
| 1 Jun 2025filed 3 Jun 2025 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —32,162 at $0.00 | filing |
| 1 Jun 2024filed 3 Jun 2024 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —28,472 at $0.00 | filing |
| 13 Jun 2023filed 15 Jun 2023 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $290K12,043 at $24.10 | filing |
| 13 Jun 2023filed 15 Jun 2023 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $19K817 at $23.45 | filing |
| 1 Jun 2023filed 2 Jun 2023 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,493 at $0.00 | filing |
| 16 May 2023filed 18 May 2023 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $220K12,207 at $18.05 | filing |
| 1 Apr 2023filed 4 Apr 2023 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 1 Apr 2023filed 4 Apr 2023 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 1 Mar 2023filed 6 Mar 2023 | DMAC DiaMedica Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —26,443 at $0.00 | filing |
| 16 May 2022filed 18 May 2022 | REPL Replimune GroupBiotechnology | SEC FORM 4 Sold | $80K5,473 at $14.59 | filing |
| 1 Apr 2022filed 5 Apr 2022 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —78,750 at $0.00 | filing |
| 1 Apr 2022filed 5 Apr 2022 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —52,500 at $0.00 | filing |
| 10 May 2021filed 11 May 2021 | REPL Replimune GroupBiotechnology | SEC FORM 4 Code A | —73,333 at $0.00 | filing |
| 10 May 2021filed 11 May 2021 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 1 Apr 2021filed 5 Apr 2021 | REPL Replimune Groupoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,500 at $0.00 | filing |
| 25 Feb 2021filed 1 Mar 2021 | KPTI Karyopharm Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —59,968 at $0.00 | filing |
| 25 Feb 2021filed 1 Mar 2021 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Code A | —22,013 at $0.00 | filing |
| 11 Feb 2021filed 17 Feb 2021 | KPTI Karyopharm TherapeuticsBiotechnology | SEC FORM 4 Sold | $32K2,046 at $15.52 | filing |
News
No headline names them, or the companies they trade most, lately.